Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: Results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 4, 2010, Pages 459-467

  Biedenbach, Douglas J ^a   Farrell, David J ^a   Mendes, Rodrigo E ^a   Ross, James E ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Global surveillance; Linezolid; MRSA; Staphylococcus aureus; VRE

Indexed keywords

BACTERIAL PROTEIN; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; RETAPAMULIN; RIBOSOMAL PROTEIN L4; RIBOSOME PROTEIN; RIBOSOME PROTEIN L3; RNA 23S; TEICOPLANIN; TETRACYCLINE; TIAMULIN; UNCLASSIFIED DRUG; VANCOMYCIN; VIRGINIAMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS; GENE MUTATION; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ADULT; AGED; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; POPULATION SURVEILLANCE; SPECIES SPECIFICITY; WORLD HEALTH;

EID: 78649257772     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.09.018     Document Type: Article

References (44)

1. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int. J. Antimicrob. Agents 2005, 26:13-21.
2. Ballow C.H., Biedenbach D.J., Rossi F., Jones R.N. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) Antimicrobial Potency Study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 2002, 6:100-109.
3. Ballow C.H., Jones R.N., Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 2002, 43:75-83.
4. Beibei L., Yun C., Mengli C., Nan B., Xuhong Y., Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 2010, 35:3-12.
5. Bell J.M., Turnidge J.D., Ballow C.H., Jones R.N. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J. Antimicrob. Chemother. 2003, 51:339-345.
6. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 2002, 8:791-800.
7. Bounthavong M., Hsu D.I. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr. Med. Res. Opin. 2010, 26:407-421.
8. Clinical and Laboratory Standards Institute (CLSI) M02-A10. Performance standards for antimicrobial disk susceptibility tests; approved standard: tenth edition 2009, CLSI, Wayne, PA.
9. Clinical and Laboratory Standards Institute (CLSI) M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eighth edition 2009, CLSI, Wayne, PA.
10. Clinical and Laboratory Standards Institute (CLSI) M100-S20. Performance standards for antimicrobial susceptibility testing: 20th informational supplement 2010, CLSI, Wayne, PA.
11. Dehghanyar P., Burger C., Zeitlinger M., Islinger F., Kovar F., Muller M., Kloft C., Joukhadar C. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob. Agents Chemother. 2005, 49:2367-2371.
12. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
13. Eliopoulos G.M. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect 2009, 59(Suppl 1):S17-S24.
14. EUCAST (2010) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1, April 2010. Available at Accessed June 10, 2010. http://www.eucast.org/clinical_breakpoints.
15. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 2003, 51(Suppl 2):ii45-ii53.
16. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 2006, 27:300-302.
17. Gomez-Gil R., Romero-Gomez M.P., Garcia-Arias A., Ubeda M.G., Busselo M.S., Cisterna R., Gutierrez-Altes A., Mingorance J. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn. Microbiol. Infect. Dis. 2009, 65:175-179.
18. Honeybourne D., Tobin C., Jevons G., Andrews J., Wise R. Intrapulmonary penetration of linezolid. J. Antimicrob. Chemother. 2003, 51:1431-1434.
19. Ikeda-Dantsuji Y., Hanaki H., Sakai F., Tomono K., Takesue Y., Honda J., Nonomiya Y., Suwabe A., Nagura O., Yanagihara K., Mikamo H., Fukuchi K., Kaku M., Kohno S., Yanagisawa C., Nakae T., Yoshida K., Niki Y. Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan. J. Infect. Chemother. 2010, (In press).
20. Jones R.N., Ballow C.H., Biedenbach D.J. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 2001, 40:59-66.
21. Jones R.N., Della-Latta P., Lee L.V., Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 2002, 42:137-139.
22. Jones R.N., Fritsche T.R., Sader H.S., Ross J.E. Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect. Dis. 2007, 59:199-209.
23. Jones R.N., Kohno S., Ono Y., Ross J.E., Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 2009, 64:191-201.
24. Jones R.N., Ross J.E., Bell J.M., Utsuki U., Fumiaki I., Kobayashi I., Turnidge J.D. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis. 2009, 65:404-413.
25. Jones R.N., Ross J.E., Fritsche T.R., Sader H.S. Oxazolidinone susceptibility patterns in 2004: Report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 2006, 57:279-287.
26. Liakopoulos A., Neocleous C., Klapsa D., Kanellopoulou M., Spiliopoulou I., Mathiopoulos K.D., Papafrangas E., Petinaki E. A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of Staphylococcus epidermidis. J. Antimicrob. Chemother. 2009, 64:206-207.
27. Liakopoulos A., Spiliopoulou I., Damani A., Kanellopoulou M., Schoina S., Papafragas E., Marangos M., Fligou F., Zakynthinos E., Markris D., Protonotariou E., Tsiapara F., Filos K., Diza E., Anastassiou E.D., Petinaki E. Dissemination of two internaitonal linezolid-resistant Staphylococcus epidermidis clones in Greek hospitals. J. Antimicrob. Chemother. 2010, 65:1070-1071.
28. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents. Chemother. 2006, 50:2500-2505.
29. Meka V.G., Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 2004, 39:1010-1015.
30. Meka V.G., Pillai S.K., Sakoulas G., Wennersten C., Venkataraman L., DeGirolami P.C., Eliopoulos G.M., Moellering R.C., Gold H.S. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 2004, 190:311-317.
31. Mendes R.E., Deshpande L., Rodriguez-Noriega E., Ross J.E., Jones R.N., Morfin-Otero R. First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization. J. Clin. Microbiol. 2010, 48:3041-3043.
32. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 2008, 52:2244-2246.
33. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 2003, 138:135-142.
34. Morales G., Picazo J.J., Baos E., Candel F.J., Arribi A., Pelaez B., Andrade R., de la Torre M.A., Fereres J., Sanchez-Garcia M. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 2010, 50:821-825.
35. Mutnick A.H., Enne V., Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 2003, 37:769-774.
36. Ross J.E., Anderegg T.R., Sader H.S., Fritsche T.R., Jones R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 2005, 52:53-58.
37. Ross J.E., Fritsche T.R., Sader H.S., Jones R.N. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents 2007, 29:295-301.
38. Schulte B., Heininger A., Autenrieth I.B., Wolz C. Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiol. Infect. 2008, 136:1131-1133.
39. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert. Opin. Investig. Drugs. 1999, 8:1195-1202.
40. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., Ferraro M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
41. Tygacil Package Insert Wyeth Pharmaceuticals 2009, Philadelphia, PA.
42. Wong A., Reddy S.P., Smyth D.S., Aguero-Rosenfeld M.E., Sakoulas G., Robinson D.A. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob. Agents. Chemother. 2010, 54:742-748.
43. Yoshida K., Shoji H., Hanaki H., Yanagisawa C., Ikeda-Dantsuji Y., Fukuchi K., Adachi M., Niki Y. Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J. Infect. Chemother. 2010, 15:417-419.
44. Zyvox Package Insert 2008, Pfizer, Inc, New York, NY.